GC Green Cross Wellbeing: Product Supply and Marketing
Boryung: Responsible for Expanding Prescriptions and Sales

GC Green Cross Wellbeing is partnering with Boryung to expand the presence of its chronic liver disease treatment “Laennec Injection” in the secondary hospital market.

(From left) Sangho Bae, Head of Hospital Division at Boryung, Woongje Jung, Vice President at Boryung, Sanghyun Kim, CEO of GC Green Cross Wellbeing, and Junghyup Han, Head of IP Division at GC Green Cross Wellbeing, are taking a commemorative photo after signing a co-promotion agreement at the GC Green Cross Wellbeing headquarters in Seongdong-gu, Seoul. GC Green Cross Wellbeing

(From left) Sangho Bae, Head of Hospital Division at Boryung, Woongje Jung, Vice President at Boryung, Sanghyun Kim, CEO of GC Green Cross Wellbeing, and Junghyup Han, Head of IP Division at GC Green Cross Wellbeing, are taking a commemorative photo after signing a co-promotion agreement at the GC Green Cross Wellbeing headquarters in Seongdong-gu, Seoul. GC Green Cross Wellbeing

View original image

On September 22, GC Green Cross Wellbeing announced that on September 11, the company signed a co-promotion agreement with Boryung at the GC Green Cross Wellbeing headquarters in Seongdong-gu, Seoul. The agreement covers the co-promotion of “Laennec Injection,” a human placenta hydrolysate injection, targeting secondary hospitals.


Through this agreement, GC Green Cross Wellbeing plans to leverage Boryung’s business network in secondary hospitals to expand market access for Laennec Injection and further strengthen its prescription base, building on the product’s competitive advantages.


GC Green Cross Wellbeing will be responsible for supplying Laennec Injection, marketing, and providing specialized product and clinical information. Boryung, utilizing its nationwide sales network and expertise in secondary hospitals, will focus on expanding prescriptions and sales for Laennec Injection. Both companies will work together to reinforce cooperation at the field level through joint marketing and other initiatives.


In particular, GC Green Cross Wellbeing aims to use this collaboration to broaden the prescription base for Laennec Injection—from its foundation among clinics and smaller medical facilities to secondary hospitals—thereby securing a new platform for ongoing growth.


Laennec Injection is a human placenta hydrolysate injectable, an ethical pharmaceutical product approved for improving liver function in the treatment of chronic liver diseases. As a flagship product for GC Green Cross Wellbeing, its prescription base has been steadily expanded across Korea.


Recently, the product’s effectiveness was also demonstrated in a phase 3 clinical trial evaluating high-dose intravenous (IV) administration to enhance convenience and expand prescription options. In the trial, conducted at 18 centers in Korea with 226 chronic liver disease patients, the primary endpoint at six weeks—the change in ALT levels—showed a statistically significant improvement in the IV group compared to the subcutaneous group. GC Green Cross Wellbeing is now working to expand intravenous administration indications for Laennec Injection based on these clinical results.


Sanghyun Kim, CEO of GC Green Cross Wellbeing, said, “This partnership will serve as an opportunity to further strengthen Laennec Injection’s competitiveness in the secondary hospital market by combining the product’s advantages with Boryung’s network in this sector. We will continue to improve access to Laennec prescriptions and enhance our competitiveness to ensure sustainable growth in the chronic liver disease treatment market.”



Woongje Jung, Vice President at Boryung, stated, “Laennec Injection is a product that has built strong competitiveness in the Korean market over a long period. We will closely cooperate with GC Green Cross Wellbeing, utilizing Boryung’s hospital sales capabilities to expand prescription opportunities for Laennec Injection in the secondary hospital market.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing